- Home
- ARQT vs HHH Comparison
ARQT vs HHH Comparison
Compare ARQT & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | HHH |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.8B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ARQT | HHH |
|---|---|---|
| Price | $26.54 | $65.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $34.00 | ★ $90.00 |
| AVG Volume (30 Days) | ★ 1.5M | 390.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | N/A |
| EPS | 0.03 | ★ 2.82 |
| Revenue | $376,072,000.00 | ★ $1,474,892,000.00 |
| Revenue This Year | $34.85 | $14.04 |
| Revenue Next Year | $29.39 | N/A |
| P/E Ratio | $853.67 | ★ $23.63 |
| Revenue Growth | ★ 91.34 | N/A |
| 52 Week Low | $15.10 | $61.01 |
| 52 Week High | $31.77 | $91.07 |
Technical Indicators
Market Signals| Indicator | ARQT | HHH |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 45.18 |
| Support Level | $24.91 | $62.04 |
| Resistance Level | $28.35 | $66.40 |
| Average True Range (ATR) | 1.30 | 1.61 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 40.18 | 41.86 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.